Schlumberger M J, Torlantano M
University Paris-Sud, Institut Gustave-Roussy, Rue Camille-Desmoulins, 94805 Villejuif Cedex, France.
Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Dec;14(4):601-13. doi: 10.1053/beem.2000.0105.
Papillary and follicular thyroid carcinomas are among the most curable of all cancers. However, some patients are at high risk of recurrence or even death from their cancer. Most of these patients can be identified at the time of diagnosis using well-established prognostic indicators. The extent of initial treatment and follow-up should therefore be individualized. The early discovery of persistent and recurrent disease is based on the combined use of serum thyroglobulin determination and of total body scanning with 131I. The recent availability of recombinant human thyroid stimulating hormone has greatly improved the quality of the patient's life during follow-up. Treatment of recurrences is based mainly on surgery and 131I treatment.
乳头状和滤泡状甲状腺癌是所有癌症中最可治愈的癌症之一。然而，一些患者有癌症复发甚至死亡的高风险。这些患者中的大多数在诊断时可以通过成熟的预后指标识别出来。因此，初始治疗和随访的范围应该个体化。持续性和复发性疾病的早期发现基于血清甲状腺球蛋白测定和131I全身扫描的联合应用。重组人促甲状腺激素的近期可得性极大地改善了患者随访期间的生活质量。复发的治疗主要基于手术和131I治疗。
